Koru Medical Q1 FY26 net loss narrows to $807,078; revenue climbs 22.1% to $11.76 million

• KORU Medical Systems posted net loss of USD 807,078 for the quarter ended March 31, 2026, narrowing from the year-ago period; net revenues rose 22.1% to USD 11.76 million.
• Operating loss narrowed to USD 864,923 as gross margin slipped 1.3 percentage points to 61.5%.
• Domestic core net revenues increased 11.7% to USD 7.74 million, while international core climbed 35.2% to USD 3.28 million.
• Pharma services and clinical trials net revenues more than doubled to USD 740,711.
• Company ended quarter with USD 8.77 million in cash and cash equivalents; amended credit facility extended revolver maturity to March 30, 2028, extended term loan maturity to Dec. 1, 2029, lowered interest rate floor to 5.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001161697-26-000108), on May 06, 2026, and is solely responsible for the information contained therein.